- Home
- VYGR vs SRG Comparison
VYGR vs SRG Comparison
Compare VYGR & SRG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VYGR
- SRG
- Stock Information
- Founded
- VYGR 2013
- SRG 2014
- Country
- VYGR United States
- SRG United States
- Employees
- VYGR N/A
- SRG N/A
- Industry
- VYGR Biotechnology: Pharmaceutical Preparations
- SRG Real Estate Investment Trusts
- Sector
- VYGR Health Care
- SRG Real Estate
- Exchange
- VYGR Nasdaq
- SRG Nasdaq
- Market Cap
- VYGR 231.9M
- SRG 237.7M
- IPO Year
- VYGR 2015
- SRG 2015
- Fundamental
- Price
- VYGR $4.95
- SRG $4.06
- Analyst Decision
- VYGR Strong Buy
- SRG
- Analyst Count
- VYGR 8
- SRG 0
- Target Price
- VYGR $16.71
- SRG N/A
- AVG Volume (30 Days)
- VYGR 814.4K
- SRG 96.5K
- Earning Date
- VYGR 11-11-2025
- SRG 11-11-2025
- Dividend Yield
- VYGR N/A
- SRG N/A
- EPS Growth
- VYGR N/A
- SRG N/A
- EPS
- VYGR N/A
- SRG N/A
- Revenue
- VYGR $42,580,000.00
- SRG $15,346,000.00
- Revenue This Year
- VYGR N/A
- SRG N/A
- Revenue Next Year
- VYGR $107.10
- SRG N/A
- P/E Ratio
- VYGR N/A
- SRG N/A
- Revenue Growth
- VYGR N/A
- SRG N/A
- 52 Week Low
- VYGR $2.65
- SRG $2.43
- 52 Week High
- VYGR $8.28
- SRG $4.72
- Technical
- Relative Strength Index (RSI)
- VYGR 58.14
- SRG 51.89
- Support Level
- VYGR $4.72
- SRG $3.88
- Resistance Level
- VYGR $5.55
- SRG $4.21
- Average True Range (ATR)
- VYGR 0.35
- SRG 0.17
- MACD
- VYGR -0.01
- SRG -0.04
- Stochastic Oscillator
- VYGR 54.88
- SRG 41.94
About VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
About SRG Seritage Growth Properties
Seritage Growth Properties is principally engaged in the ownership, development, redevelopment, management, and leasing of diversified and mixed-use properties throughout the United States.